No Data
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $24
Stoke Therapeutics Initiated at Buy by Chardan Capital
Stoke Therapeutics Price Target Announced at $24.00/Share by Chardan Capital
Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
Stoke Therapeutics (NASDAQ:STOK) Pulls Back 9.1% This Week, but Still Delivers Shareholders Impressive 136% Return Over 1 Year
Insider Sale: CHIEF MEDICAL OFFICER of $STOK (STOK) Sells 13,945 Shares
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
